AKT1 and metabolic dysfunction-associated steatotic liver disease: In summary, 2-HOBA treatment showed promising effects in both DIAMOND and STAM mouse models of MASLD manifested by reduced liver mass and improved liver function markers, decreased oxidative stress and inflammatory markers, improved histopathological features of MASH, and enhanced AKT/GSK3β signaling, like metformin’s effects [40].